WO2004022760A1 - Generation of recombinant influenza virus using baculovirus delivery vector - Google Patents
Generation of recombinant influenza virus using baculovirus delivery vector Download PDFInfo
- Publication number
- WO2004022760A1 WO2004022760A1 PCT/EP2003/009375 EP0309375W WO2004022760A1 WO 2004022760 A1 WO2004022760 A1 WO 2004022760A1 EP 0309375 W EP0309375 W EP 0309375W WO 2004022760 A1 WO2004022760 A1 WO 2004022760A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- baculovirus
- influenza
- modified
- virus
- Prior art date
Links
- 241000701447 unidentified baculovirus Species 0.000 title claims abstract description 99
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract description 33
- 239000013598 vector Substances 0.000 title abstract description 12
- 241000700605 Viruses Species 0.000 claims abstract description 67
- 210000004027 cell Anatomy 0.000 claims abstract description 56
- 238000000034 method Methods 0.000 claims abstract description 35
- 210000003501 vero cell Anatomy 0.000 claims abstract description 32
- 206010022000 influenza Diseases 0.000 claims abstract description 26
- 238000010361 transduction Methods 0.000 claims abstract description 23
- 230000014509 gene expression Effects 0.000 claims abstract description 22
- 230000026683 transduction Effects 0.000 claims abstract description 21
- 101150076514 NS gene Proteins 0.000 claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 148
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 230000003612 virological effect Effects 0.000 claims description 15
- 241000712431 Influenza A virus Species 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 10
- 230000002238 attenuated effect Effects 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 7
- 101710154606 Hemagglutinin Proteins 0.000 claims description 6
- 102000005348 Neuraminidase Human genes 0.000 claims description 6
- 108010006232 Neuraminidase Proteins 0.000 claims description 6
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 6
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 6
- 101710176177 Protein A56 Proteins 0.000 claims description 6
- 108700005077 Viral Genes Proteins 0.000 claims description 6
- 239000000185 hemagglutinin Substances 0.000 claims description 6
- 208000037797 influenza A Diseases 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 230000002458 infectious effect Effects 0.000 claims description 5
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 claims description 2
- 230000002457 bidirectional effect Effects 0.000 claims description 2
- 210000002845 virion Anatomy 0.000 claims description 2
- 229960001226 live attenuated influenza Drugs 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 108700008625 Reporter Genes Proteins 0.000 abstract description 9
- 238000013518 transcription Methods 0.000 abstract description 8
- 230000035897 transcription Effects 0.000 abstract description 8
- 229960003971 influenza vaccine Drugs 0.000 abstract description 4
- 101710158312 DNA-binding protein HU-beta Proteins 0.000 description 12
- 101710128560 Initiator protein NS1 Proteins 0.000 description 12
- 101710144127 Non-structural protein 1 Proteins 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 11
- 108010050904 Interferons Proteins 0.000 description 10
- 102000014150 Interferons Human genes 0.000 description 10
- 229940079322 interferon Drugs 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 241000724709 Hepatitis delta virus Species 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 101710199667 Nuclear export protein Proteins 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 241000701022 Cytomegalovirus Species 0.000 description 6
- 241000238631 Hexapoda Species 0.000 description 6
- 241000713196 Influenza B virus Species 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 108010089610 Nuclear Proteins Proteins 0.000 description 5
- 102000007999 Nuclear Proteins Human genes 0.000 description 5
- 101150115538 nero gene Proteins 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 102000053642 Catalytic RNA Human genes 0.000 description 4
- 108090000994 Catalytic RNA Proteins 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 208000037262 Hepatitis delta Diseases 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 208000029570 hepatitis D virus infection Diseases 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 108091092562 ribozyme Proteins 0.000 description 4
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 108091034135 Vault RNA Proteins 0.000 description 3
- 108010006025 bovine growth hormone Proteins 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 101150033828 NS1 gene Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000017143 RNA Polymerase I Human genes 0.000 description 2
- 102000004389 Ribonucleoproteins Human genes 0.000 description 2
- 108010081734 Ribonucleoproteins Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000037798 influenza B Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 241000701412 Baculoviridae Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 101710118188 DNA-binding protein HU-alpha Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 101710144128 Non-structural protein 2 Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 108700010900 influenza virus proteins Proteins 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000012194 insect media Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 241000856131 recombinant Influenza A viruses Species 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present invention is in the fields of recombinant gene technology and vaccine development and relates to a method for rescuing recombinant viruses, particularly recombinant orthomyxoviruses, using baculovirus as a gene shuttle for delivery of desired viral genes to a mammalian host cell for expression. It further relates to a modified baculovirus genome as used in said method, and further to the manufacture of vaccines using said method for rescuing recombinant viruses.
- influenza virus One of the most important and best characterized members of the orthomyxoviruses is influenza virus.
- the genome of influenza virus is single stranded RNA of negative polarity that comprises approximately 13500 nucleotides.
- the genome of both influenza A and B viruses is distributed into eight different segments, coding for nine structural proteins and two non-structural proteins (NS1, NS2) with regulatory functions.
- the first 12 nucleotides at the 3' end and the first 13 nucleotides at the 5' end of each genome segment of influenza A viruses are conserved in all eight segments. Due to the segmented nature of the viral genome genetic reassortment takes place when mixed infection of two different influenza strains occurs (i.e. avian influenza A strains can reassort with human influenza A viruses).
- RNP ribonucleoprotein complex
- PB1, PB2, PA the three viral polymerase proteins
- NP nuclear protein
- Reverse genetics for negative-strand viruses first developed for influenza A virus by Luytjes et al (3), has significantly contributed to our biological understanding of these pathogens and still gives rise to improving the methods of vaccine development.
- the manipulation of the influenza genome by reverse genetics has led to the possibility of preparing stable laboratory strains which contain site-directed mutations that can be designed in a way such that they confer attenuation in one or more genes.
- establishment of NS gene engineering methods for influenza A virus allowed to discover the main function of the NS1 protein as interferon antagonist and permitted obtaining genetically stable attenuated strains thatcan be used as a live influenza vaccine (4, 5).
- Baculovirus as Gene Delivery Tool Current methods of expressing genes in a mammalian cell include the use of viral vectors, such as those which are derived from retroviruses, adenoviruses, herpes viruses, vaccinia viruses, polio viruses, Sindbis viruses, or adeno-associated viruses.
- Other methods of expressing an exogenous gene in a mammalian cell include direct injection of DNA, the use of ligand-DNA conjugates, the use of adenovirus-ligand- DNA conjugates, calcium phosphate precipitation, and methods which utilize a liposome- or polycation-DNA complex.
- viruses of the family Baculoviridae have been used to express exogenous genes in insect cells and mammalian cells.
- Baculoviridaes viruses of the family Baculoviridae (commonly referred to as baculoviruses) have been used to express exogenous genes in insect cells and mammalian cells.
- One of the most studied baculoviruses is the Autographa californica multiple nuclear polyhedrosis virus (AcMNPV).
- AcMNPV Autographa californica multiple nuclear polyhedrosis virus
- the transduction of mammalian cells by baculovirus particles bears no safety risk for either product or operator.
- the expression of the exogenous genes is transient, unless a G418-resistance-gene is included and selected for by the addition of G418.
- the transient expression of a mammalian expression cassette present on the baculovirus genome is gene dosage-dependent, corresponding to the number of virus particles used in
- the invention relates to the construction of one or more baculovirus clones that are able to express one or more, optionally all, genes necessary for the rescue of infectious influenza virus.
- the baculovirus is a nuclear polyhedrosis virus and most preferably is AcMNPV.
- Baculoviruses possess several advantages that make them an attractive method for influenza genetic manipulation. Multiple genes and large inserts (up to 38 kb) can be introduced into the baculovirus genome so that one or more or even all influenza genes can be delivered to Vero cells at once.
- the baculoviruses are inherently unable to replicate in mammalian cells and are therefore considered biologically safe for therapeutic applications for humans.
- baculovirus Autographa calif ornica nuclear polyhedrosis virus (AcNPV) is an insect virus with a large double- stranded circular DNA genome.
- AcNPV baculovirus Autographa calif ornica nuclear polyhedrosis virus
- baculoviruses have primarily been used to over-express proteins from insect derived host cells, they have been demonstrated to serve as a powerful vector to carry various genes into a variety of mammalian cell types at high frequencies (8).
- baculovirus as an influenza gene delivery vector. Recombinant baculovirus harboring a truncated influenza A NS gene, resulting in a 38 amino acid long NS1 protein, was constructed.
- GFP green fluorescent protein
- subsequent infection of baculovirus-transduced Vero cells with a temperature-sensitive (ts) influenza helper virus whose NS gene segment was found to be responsible for the ts phenotype, and subsequent passages in Vero cells at 40 °C resulted in the isolation of an influenza virus carrying the baculovirus-derived truncated NS1 gene.
- This virus designated ⁇ NS38, did not grow on Madin-Darby canine kidney (MDCK) cells or in eggs, but gave almost equal titers, compared to the wild type variant, in interferon deficient Vero cells (4).
- the invention further relates to a baculovirus genome that contains one or more uni- or bidirectional expression cassettes encoding at least one natural or modified gene or gene segment or a combination of a least one natural and at least one modified gene or gene segment, of an orthomyxo virus.
- the invention relates to Baculovirus genome wherein said at least one natural or modified gene or gene segment is from influenza A or B virus.
- the invention relates to a baculovirus genome wherein said at least one natural or modified gene or gene segment encodes viral mRNA or viral genomic RNA, or both viral mRNA and viral genomic RNA.
- the invention relates to a baculovirus genome wherein said at least one natural or modified gene or gene segment is flanked by restriction sites that allow for introduction and exchange of said gene or gene segment by cleavage of said restriction sites and subsequent direct ligation of said gene(s) or gene segment(s) into the baculovirus genome. These restriction sites are unique in baculovirus.
- the invention relates to a baculovirus genome wherein said at least one natural or modified gene or gene segment comprises a modified NS gene segment of influenza virus encoding an NS1 protein of only 38 amino acids in length ( ⁇ NS38), wherein the 38 amino acids are the N-terminal starting sequence of the NS1 protein.
- the big C-terminal truncation of the NS1 amino acid sequence renders the influenza virus interferon inducing and, simultaneously, interferon sensitive, which has in effect that the resulting virus is attenuated (at least due to its susceptibility to IFN activity) and thus a promising candidate for making live vaccines.
- the invention relates to a baculovirus genome wherein said at least one natural or modified gene or gene segment comprises a modified NS gene segment of influenza virus, a hemagglutinin (HA) and/or a neuraminidase (NA) gene segment of an epidemic influenza strain, and all remaining gene segments of the epidemic strain or of one or more other influenza wildtype or laboratory master strains.
- said at least one natural or modified gene or gene segment comprises a modified NS gene segment of influenza virus, a hemagglutinin (HA) and/or a neuraminidase (NA) gene segment of an epidemic influenza strain, and all remaining gene segments of the epidemic strain or of one or more other influenza wildtype or laboratory master strains.
- the AcMNPV genome comprises 134 kbp of double-stranded DNA.
- the capacity of foreign gene insertion into the baculovirus genome has been demonstrated to be at least 40 kbp of DNA. Therefore, it becomes possible to stably integrate more than one gene-expression cassette into the AcNPV genome, e.g. target gene plus reporter gene, protein complexes consisting of multiple subunits.
- the baculovirus genome can carry an exogenous promoter positioned for expression of the exogenous gene.
- Preferred promoters include the cytomegalovirus early promoter (CMV) and the human ribosomal RNA polymerase I promoter (Pol-I).
- the baculovirus genome may also carry a polyadenylation signal, the bovine growth hormone poly adenylation signal (BGH-Poly A) or the hepatitis delta virus genomic ribozyme (HDN), a self-cleaving R ⁇ A sequence which ensures the correct 3 ' end.
- BGH-Poly A bovine growth hormone poly adenylation signal
- HDN hepatitis delta virus genomic ribozyme
- the baculovirus is engineered to contain as a heterologous insertion into its genome at least one", preferably several, optionally all genes or gene segments of influenza virus, or of any other orthomyxovirus.
- Influenza A as well as B viruses possess a segmented single-stranded, negative-strand R ⁇ A genome.
- All R ⁇ A-segments must be produced as negative strand viral genomic R ⁇ A (vR ⁇ A) and four of these R ⁇ A segments must be present either as functional proteins or as transcripts encoding proteins that have to be functional for transcription and replication of all segments.
- the different Orthomyxovirus genes may be engineered in any combination or number into a single baculovirus genome or may be divided into two or more portions and distributed to two or more separate baculovirus genomes.
- a baculovirus containing just one foreign gene e.g. a modified version of the ⁇ S1 gene, may be used for transduction of Nero cells and rescue of infectious virus, e.g. influenza virus or any orthomyxovirus, may be carried out via superinfection with helper virus.
- co- transduction of several baculoviruses, each 1 containg one or more different orthomyxovirus genes, may be carried out in order to rescue infectious orthomyxovirus particles, preferably without the aid of helper virus.
- transduction refers to carrier-mediated transfer of genetic material to a living host cell, wherein the carrier is an enveloped virus and the genetic material is contained within the capsid of said virus, and wherein the transfer is accomplished in a way such that upon contact of the virus with the host cell the capsid containing the genetic material penetrates the host cell and migrates to the host cell's nucleus, while the viral envelope remains outside the host cell.
- the baculovirus used according to the present invention is such a viral carrier.
- transfection refers to the transfer, usually carrier-mediated transfer, of naked RNA or DNA, e.g. plasmid RNA or DNA vector constructs, to host cells.
- Suitable carriers are, for instance, RNP (ribonucleoprotein complex) or lipids (e.g. Lipofectin ® ).
- infection refers to the exposure of host cells to natural or modified viruses and the subsequent delivery of viral RNA or DNA to the host cell using natural pathways, including, as the case may be, penetration of the host cell by the whole virus.
- the term applies to the delivery of influenza virus RNA gene segments to a host cell, e.g. a Nero cell, using an influenza wildtype or helper virus.
- a baculovirus-delivered, truncated NS1 gene from influenza A virus ( ⁇ NS38-gene) was expressed in Vero cells and transcribed vRNA was successfully incorporated into influenza virus particles.
- RT-PCR with PR8 and helper virus-specific primers was performed after plaque purification (Fig. 2).
- a mixture of the truncated ⁇ NS38-vRNA and helper virus NS-vRNA was detected after two selective passages at 40°C. After several plaque purification steps, a homogenous virus population could be isolated and the ⁇ NS38 gene was confirmed by nucleotide sequence analysis.
- Recombinant ⁇ NS38 virus showed similar growth patterns in interferon-deficient Vero cells as compared to the 25 A- 1 helper virus (a reassortant virus containing the NS segment form the cold-adapted influenza strain A/Leningrad/134/47/57 and the remaining genes from influenza A/PR/8/34) but was fully restricted from growth on MDCK cells or in eggs.
- the baculovirus was shown for its effective delivery of foreign genes into Vero cells. Transduction efficiency of the recombinant baculovirus at different MOIs into Vero cells was evaluated, using GFP as a reporter gene. FACS analysis revealed that the Vero cell transduction was concentration-dependent (FIG.2B). More than 90% of the cells were transduced when recombinant baculovirus was used at MOI 5000, as evidenced by their expression of GFP 24 to 48 hours after transduction. Although high numbers of baculovirus particles may be required, this method is considered feasible and significantly superior to the afore-mentioned methods known in the art, since baculoviruses can be easily generated and grown to high titers in insect cells.
- the truncated NS1 protein of this virus consisting of only 38 N-terminal amino acids, is responsible for the attenuated phenotype in mice, which is based on the finding that ⁇ NS38 virus has an interferon inducing but also an interferon sensitive phenotype.
- some or all genes of the desired recombinant Orthomyxovirus are inserted into the genome of a single baculovirus and thereafter transduced into Vero cells for expression of the viral genes and for assembly and release of the desired recombinant Orthomyxoviruses.
- some or all of the genes or gene segments, respectively, of the desired recombinant virus are divided into two portions and distributed into the genomes of two baculoviruses and thereafter co-transduced into Vero cells for expression and assembly of recombinant virus.
- the term "desired” virus shall mean any virus having a pre-selected phenotype, preferably having an attenuated (e.g. temperature-sensitive, interferon-sensitive, or otherwise replication-inhibited) phenotype, and/or a pre-selected set of genes or gene segments.
- the desired virus be an influenza virus that comprises a modified NS gene segment responsible for interferon induction and/or for interferon sensitivity such as the ⁇ NS38 gene segment (coding for a full NEP and a truncated NS1 protein of only 38 amino acids length), a hemagglutinin (HA) and/or a neuraminidase (NA) gene segment of an epidemic influenza virus strain, and some or all of the remaining gene segments of one or more other influenza wildtype or laboratory master strains.
- a modified NS gene segment responsible for interferon induction and/or for interferon sensitivity such as the ⁇ NS38 gene segment (coding for a full NEP and a truncated NS1 protein of only 38 amino acids length), a hemagglutinin (HA) and/or a neuraminidase (NA) gene segment of an epidemic influenza virus strain, and some or all of the remaining gene segments of one or more other influenza wildtype or laboratory master strains.
- HA hemag
- the present invention also encompasses an embodiment, wherein a part or the entirety of genes or gene segments, respectively, of a desired recombinant virus, are split into more than two portions and distributed to more than two baculovirus genomes, each baculovirus genome receiving just one of said more than two portions of genes or gene segments, respectively.
- the recombinant baculoviruses produced by this method and differing from one another by the inserted portion of foreign genes or gene segments are then co-transduced to the host cells, preferably Vero cells, for expression of the viral genes and assembly and release of the desired recombinant virus particles. Both methods have in common that they do not require the use of a helper virus to rescue the desired recombinant virus.
- helper viruses wherein the transduced genes or gene segments replace the corresponding genes or gene segments of the helper virus.
- this method requires the employment of a helper virus and a suitable subsequent selection system for rescuing the desired recombinant reassorted viruses (i.e. the modified helper viruses), it is still more efficient than all other reverse genetic methods known to us so far.
- Fig. 1 Construction of recombinant NS expressing cassette.
- the NS gene was cloned in reverse orientation between human polymerase I promoter (Poll) and hepatitis delta virus terminator (HDV) to transcribed NS vRNA.
- a multiple stop codon cassette was introduced, resulting in a truncated, 38 amino acid NS1 protein and a full size, 121 aa NEP.
- the non- translated part between the stop codon and the splicing signal of NEP was deleted.
- Fig. 2 Expression of the reporter gene (GFP) in infected Vero cells depending upon baculovirus concentration.
- GFP reporter gene
- Vero cells were transduced with baculovirus carrying a GFP reporter gene at different MOIs. Using FACS analysis, the percentage of GFP expressing cells was measured (i.e. reflecting cells are transduced with baculovirus).
- Fig. 3 Detection of the recombinant influenza NS gene.
- Virus-containing supernatant obtained from Vero cell culture after transduction with baculovirus and subsequent infection with influenza helper virus, was passaged twice at 40°C and analyzed by RT-PCR, using two sets of primers which selectively detect only wild-type (lane 1) or only recombinant, truncated gene (lane 2)
- the supernatant comprises a mixture of helper virus 25 A- 1 and rescued ⁇ NS38 virus (Fig. 3 A).
- Fig. 3B After several plaque purification steps a pure recombinant ⁇ NS38 virus was isolated (Fig. 3B).
- Influenza virus 25 A- 1 is a temperature-sensitive (ts) reassortant containing the NS gene from the cold-adapted strain A/Leningrad/134/47/57 (H2N2) and the remaining genes from the A/Puerto Rico/8/34 (H1N1) virus.
- the NS gene is responsible for the temperature-sensitive phenotype of the helper virus.
- the virus was amplified in Vero cells in serum free medium.
- the NS gene was cloned between human ribosomal polymerase I promoter (Poll) and hepatitis delta virus genomic ribozyme (HDV), a self-cleaving RNA sequence which ensures the correct 3' end.
- a multiple stop codon cassette was introduced after the nuclear localization signal 1 (NLS1) of the NS1 protein.
- the non-translated part between this stop codon cassette and the splicing signal of the nuclear export protein (NEP) was deleted and resulted in a truncated NS1 protein, consisting of only 38 amino acids but a fully intact NEP protein (6).
- the NS construct, designated ⁇ NS38 was inserted into a baculovirus transfer vector (pCMVGFP), a modified pBacPA (Clonetech), expressing the green fluorescence protein (GFP) under control of the cytomegalovirus promoter (CMV) and the bovine growth hormone polyadenylation site (BGH) as reporter-gene.
- pCMVGFP- ⁇ NS38 a baculovirus transfer vector
- CMV cytomegalovirus promoter
- BGH bovine growth hormone polyadenylation site
- the recombinant plasmid (pCMVGFP- ⁇ NS38) and linear AcNPY viral DNA (Baculogold, PharMingen) were co-transfected into Spodoptera frugiperda (S ⁇ ) insect cells and recombinant AcCMVGFP- ⁇ NS38 baculoviruses were generated.
- the recombinant AcCMVGFP- ⁇ NS38 baculoviruses were purified by
- Vero cells were transduced with recombinant AcCMVGFP- ⁇ NS38 baculovirus, carrying a GFP reporter gene at different MOIs using the procedure described above. After 48 hours, the transduced cells were trypsinized and resuspended in PBS. GFP expressing cells were analyzed by a fluorescence activated cell sorter (FACS).
- FACS fluorescence activated cell sorter
- Influenza B virus genes of strain B Lee 40 were released from the cloning vector backbone pHW2000 by restriction digests and inserted into the baculovirus transfer vector pBacPAK ⁇ . More particularly, the three polymerase genes and the gene encoding the nuclear protein of influenza B virus (B Lee 40), were taken from the constructs pHW-Lee-PBl, pHW-Lee-PB2, pHW-Lee-PA, pHW-Lee-NP, which are based on pHW2000 (Hoffmann et al, 2000), kindly received from Thorsten Wolff (Robert Koch-Institute, Berlin) and were inserted each into a baculovirus transfer vector pBacPAK8 (Clontech).
- the genes are expressed bidirectionally, transcription (i.e. generation) of the messenger RNA is driven by the cytomegalovirus (CMV) early promoter and terminated by the bovine growth hormone (BGH) polyadenylation signal. Transcription (i.e. generation) of genomic RNA is driven by the human polymerase I (Pol I) promoter and terminated by the hepatitis delta virus (HDV) genomic ribozyme, a self-cleaving RNA sequence to ensure the correct 3' end (Neuman et al., 1994). This set of proteins is required for reverse transcription of influenza virus genes and genes that are flanked by influenza virus non-coding sequences, where the nuclear complex binds and initiates transcription.
- CMV cytomegalovirus
- BGH bovine growth hormone
- HDV hepatitis delta virus
- Recombinant baculovirus clones were generated via homologous recombination using the above described transfer vectors, and amplified and purified by sucrose gradient centrifugation.
- a plasmid was constructed, which contained the green fluorescent protein (gfp) in minus sense orientation, flanked by influenza B virus non-coding sequences.
- the gene encoding minus sense RNA of green fluorescent protein is expressed under control of the human polymerase I promoter (Poll) and terminated by the hepatitis delta virus genomic ribozyme (HDV).
- the RNP-complex comprising the four influenza B virus proteins (PA, PBl, PB2, NP) binds to the non-coding region and initiates transcription. Only when all four influenza virus proteins comprised in the nuclear complex (PBl, PB2, NP, PA) are functionally active hence successfully delivered and expressed, gfp mRNA is being produced and gfp expression can be detected by a fluorescent signal.
- HEK293 Freestyle cells Invitrogen were transduced with a pool of the four baculovirus clones, using a total moi of either 50, 500, 1000, 5000 or 7500.
- cells 48 hours post transduction, cells were transfected with 1 ⁇ g of purified plasmid containing the minus sense gfp gene flanked by influenza B virus non-coding sequences. Analysis was performed 24 hours post transfection by fluorescence activated cell sorting.
- gfp was functionally expressed in the HEK293 freestyle cells due to transcriptional activity of the influenza B virus nuclear complex which formed and assembled within the cells upon delivery and expression of the four different baculovirus clones.
- the principle underlying the present invention as claimed herein was fully confirmed. Particularly, it was proven that the present invention allows not only for successful delivery of several different genes of interest to a mammalian host cell using the baculovirus-based transduction system but also for successful expression of the delivered genes.
- each clone comprising another influenza virus gene or gene segment can likewise result in successful transcription and expression of the delivered genes and subsequent assembly of the expressed proteins to form virus particles.
- RNA polymerase I mediates expression of influenza virual RNA molecules. Virology, 202, 477-479.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003270099A AU2003270099A1 (en) | 2002-09-04 | 2003-08-23 | Generation of recombinant influenza virus using baculovirus delivery vector |
EP03750434A EP1534845A1 (en) | 2002-09-04 | 2003-08-23 | Generation of recombinant influenza virus using baculovirus delivery vector |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40769502P | 2002-09-04 | 2002-09-04 | |
US60/407,695 | 2002-09-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004022760A1 true WO2004022760A1 (en) | 2004-03-18 |
Family
ID=31978508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/009375 WO2004022760A1 (en) | 2002-09-04 | 2003-08-23 | Generation of recombinant influenza virus using baculovirus delivery vector |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1534845A1 (en) |
AU (1) | AU2003270099A1 (en) |
WO (1) | WO2004022760A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011012999A1 (en) * | 2009-07-31 | 2011-02-03 | Novartis Ag | Reverse genetics systems |
WO2013014400A1 (en) * | 2011-07-27 | 2013-01-31 | Genethon | Baculovirus system for the expression of a gene therapy vector |
US8513006B2 (en) | 2010-09-14 | 2013-08-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Tetravalent influenza vaccine and use thereof |
-
2003
- 2003-08-23 AU AU2003270099A patent/AU2003270099A1/en not_active Abandoned
- 2003-08-23 WO PCT/EP2003/009375 patent/WO2004022760A1/en not_active Application Discontinuation
- 2003-08-23 EP EP03750434A patent/EP1534845A1/en not_active Withdrawn
Non-Patent Citations (2)
Title |
---|
JOHANSSON B E: "Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 17, no. 15-16, 9 April 1999 (1999-04-09), pages 2073 - 2080, XP004165058, ISSN: 0264-410X * |
POOMPUTSA K ET AL: "Generation of recombinant influenza virus using baculovirus delivery vector", JOURNAL OF VIROLOGICAL METHODS, vol. 110, pages 111 - 114, XP002264078 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017189179A (en) * | 2009-07-31 | 2017-10-19 | ノバルティス アーゲー | Reverse genetics system |
AU2010277310B2 (en) * | 2009-07-31 | 2015-01-15 | Seqirus UK Limited | Reverse genetics systems |
US10610584B2 (en) | 2009-07-31 | 2020-04-07 | Seqirus UK Limited | Reverse genetics systems |
WO2011012999A1 (en) * | 2009-07-31 | 2011-02-03 | Novartis Ag | Reverse genetics systems |
CN104862335A (en) * | 2009-07-31 | 2015-08-26 | 诺华股份有限公司 | Reverse genetics systems |
US9821052B2 (en) | 2009-07-31 | 2017-11-21 | Seqirus UK Limited | Reverse genetics systems |
JP2013500712A (en) * | 2009-07-31 | 2013-01-10 | ノバルティス アーゲー | Reverse genetics |
US8513006B2 (en) | 2010-09-14 | 2013-08-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Tetravalent influenza vaccine and use thereof |
US20140349374A1 (en) * | 2011-07-27 | 2014-11-27 | Genethon | Baculovirus system for the expression of a gene therapy vector |
FR2978456A1 (en) * | 2011-07-27 | 2013-02-01 | Genethon | BACULOVIRAL SYSTEM FOR THE EXPRESSION OF A GENE THERAPEUTIC VECTOR |
AU2012288681B2 (en) * | 2011-07-27 | 2017-08-17 | Genethon | Baculovirus system for the expression of a gene therapy vector |
US10017783B2 (en) * | 2011-07-27 | 2018-07-10 | Genethon | Baculovirus system for the expression of a gene therapy vector |
WO2013014400A1 (en) * | 2011-07-27 | 2013-01-31 | Genethon | Baculovirus system for the expression of a gene therapy vector |
US10767192B2 (en) | 2011-07-27 | 2020-09-08 | Genethon | Baculovirus system for the expression of a gene therapy vector |
Also Published As
Publication number | Publication date |
---|---|
EP1534845A1 (en) | 2005-06-01 |
AU2003270099A1 (en) | 2004-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5702321B2 (en) | Influenza virus rescue | |
EP1194580B2 (en) | In vitro reconstitution of segmented negative-strand rna viruses | |
JP5303603B2 (en) | Multiple plasmid system for the production of influenza virus | |
JP5215561B2 (en) | High-titer recombinant influenza virus for vaccines and gene therapy | |
JP5438065B2 (en) | Virus encoding a mutated membrane protein | |
US8043856B2 (en) | Adenoviral vectors for influenza virus production | |
EP1748790B1 (en) | Multi plasmid system for the production of influenza virus | |
CA2526834A1 (en) | Recombinant influenza vectors with a polii promoter and ribozymes | |
US20090017444A1 (en) | Screening method for modulators of viral transcription or replication | |
Machado et al. | Expression of a foreign gene by stable recombinant influenza viruses harboring a dicistronic genomic segment with an internal promoter | |
EP1534845A1 (en) | Generation of recombinant influenza virus using baculovirus delivery vector | |
Poomputsa et al. | Generation of recombinant influenza virus using baculovirus delivery vector | |
US20140161771A1 (en) | Recombinant influenza viruses and constructs and uses thereof | |
EP1200563B1 (en) | Attenuated influenza virus useful as vaccine | |
JP2002513575A (en) | Attenuated influenza virus | |
PT1194580E (en) | In vitro reconstitution of segmented negative-strand rna viruses | |
US12098382B2 (en) | Recombinant influenza viruses and constructs and uses thereof | |
Nakowitsch et al. | Optimization of baculovirus transduction on freestyle TM 293 cells for the generation of influenza B/Lee/40 | |
Class et al. | Patent application title: RECOMBINANT INFLUENZA VIRUSES AND CONSTRUCTS AND USES THEREOF Inventors: Daniel R. Perez (Olney, MD, US) Daniel R. Perez Hongjun Chen (Hyattsville, MD, US) Hongjun Chen Yibin Cai (Hyattsville, MD, US) Yibin Cai Lindomar Jose Pena Lindomar Jose Pena (College Park, MD, US) Matthew Angel (Greenbelt, MD, US) Matthew Angel | |
Kawaoka et al. | Recombinant influenza vectors with a PolII promoter and ribozymes for vaccines and gene therapy | |
Hayman et al. | WedyH wadA A? ABA | |
MXPA05012700A (en) | Recombinant influenza vectors with a polii promoter and ribozymes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003750434 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003750434 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003750434 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |